Aug 11, 2020
Eisai Announces Topline Results from Study 211 Supporting 24 mg as the Appropriate Starting Dose for LENVIMA® (lenvatinib) in Patients with Differentiated Thyroid Cancer
Apr 28, 2020
Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor
Apr 24, 2020
Sumitovant Biopharma Reports Key Clinical and Regulatory Milestones by Myovant Sciences
Apr 13, 2020
Ascletis Receives IND Approval for its HIV Drug ASC09F
Mar 25, 2020
Mylan Announces Additional Efforts to Support Response to the COVID-19 Pandemic by Voluntarily Waiving its Marketing Exclusivity in the U.S. for Lopinavir/Ritonavir to Help Ensure Wider Availability to Meet Potential COVID-19 Patient Needs
Mar 19, 2020
Positive Results from Registrational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) in Advanced Endometrial Carcinoma Published in the Journal of Clinical Oncology
Mar 09, 2020
AbbVie Partnering with Global Authorities to Determine Efficacy of HIV Drug in Treating COVID-19
Feb 15, 2020
Eisai Announces Latest Data for LENVIMA® (lenvatinib) in Combination with Everolimus for Advanced Non-Clear Cell Renal Cell Carcinoma
Feb 10, 2020
Eisai to Present Latest on LENVIMA® (lenvatinib) at the 2020 Genitourinary Cancers Symposium
Jan 24, 2020
CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib
Jan 21, 2020
Eisai to Present Latest Data on LENVIMA® (lenvatinib) at the 2020 Gastrointestinal Cancers Symposium
Sep 20, 2019
Bayer data at ESMO 2019 highlights innovation in cancer research
Sep 03, 2019
True Diagnostics(TM) and Veravas, Inc. Announce Strategic Alliance in the Commercialization of VeraTest Biotin(TM)
Aug 28, 2019
Lannett Enters Into Distribution Agreement For Posaconazole Delayed-Release Tablets; Launch To Commence Shortly
Aug 27, 2019
FINAL DEADLINE - Acer Therapeutics Inc. (ACER) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: August 30, 2019
Aug 22, 2019
Snap Bio's Lead Candidate Overcomes Resistance of Approved Drugs for Liver Cancer
Aug 14, 2019
Allantoin Markets, 2019 - Global Analysis, Trends, and Forecasts to 2025 - ResearchAndMarkets.com
Jun 19, 2019
Bayer's Stivarga® (regorafenib) becomes first compound used in clinical trial platform to investigate new therapies for brain cancer
Jun 09, 2019
CStone and Bayer announce global collaboration to evaluate PD-L1 monoclonal antibody CS1001 in combination with regorafenib
May 14, 2019
Daiichi Sankyo Announces Outcome of FDA Oncologic Drugs Advisory Committee Meeting to Review FLT3 Inhibitor Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML